Drug resistance gene expression

“Drug resistance gene expression” refers collectively to the set of changes in mRNA levels across multiple genes within cells that have become resistant to therapeutic agents such as chemotherapy drugs or antibiotics. These changes can include upregulation or downregulation of various functional classes—such as transporters responsible for pumping out drugs from cells; enzymes modifying/inactivating drugs; anti-apoptotic factors preventing cell death; DNA repair proteins counteracting cytotoxic damage; and regulators influenced by the tumor microenvironment. Rather than being a single molecular entity suitable for direct pharmacological targeting, this concept represents an important area for biomarker discovery and systems-level understanding aimed at overcoming treatment failure due to acquired cellular adaptation mechanisms.

Other names

Drug resistance signatureDrug-resistant gene profileResistance-associated differentially expressed genes (R-DEGs)Chemoresistance gene signature

Drugs may be designed to inhibit proteins encoded by upregulated genes contributing to drug efflux (e.g., ABC transporters), anti-apoptotic proteins (e.g., BCL2 family), DNA repair enzymes (e.g., PARP), etc. Some strategies involve modulating epigenetic marks that control these genes' transcription.